Lynparza + Recentin: Data from P2/3 trial (NCT02502266) for recurrent platinum resistant/refractory ovarian cancer in 2021 or later (AstraZeneca) - Apr 29, 2020 - Q1 2020 Results
P2/3 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor
|